Digest Network Come funziona
Network
/
Società
Ge
Non verificato

Genmab A/S

Di cosa scriviamo

BiotecnologiaFarmaceuticaMedicina - VarieOncologiaSalute

22 comunicati stampa

Guarda tutti i comunicati
18/11/2025
Igiene alimentare
Salute
Medicina - Varie
Sanità
Farmaceutica
Biotecnologia
Industria
Genmab Announces EPKINLY® (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide Approved by the U.S. Food and Drug Administration for the Treatment of Relapsed or Refractory Follicular Lymphoma
Fonte
Genmab A/S
Emittente
Business Wire
1.00
0
03/11/2025
Scienza
Biotecnologia
Farmaceutica
Oncologia
Sanità
Salute
Medicina - Varie
Industria
Genmab to Showcase Latest Blood Cancer Treatment Advancements at 2025 American Society of Hematology (ASH) Annual Meeting
Fonte
Genmab A/S
Emittente
Business Wire
1.00
0
29/09/2025
Biotecnologia
Salute
Oncologia
Medicina - Varie
Mercato azionario
Genmab to Acquire Merus, Expanding Late-Stage Pipeline and Accelerating into a Wholly Owned Model
Fonte
Genmab A/S
Emittente
Business Wire
1.00
0
03/09/2025
Oncologia
Salute
Medicina - Varie
Farmaceutica
Cardiologia
Biotecnologia
Eventi
Industria
Genmab Announces Updated Results from Phase 2 EPCORE® NHL-6 Study Evaluating Epcoritamab Monotherapy in the Outpatient Setting in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)
Fonte
Genmab A/S
Emittente
Business Wire
1.00
0
26/08/2025
Oncologia
Igiene alimentare
Salute
Medicina - Varie
Farmaceutica
Biotecnologia
Industria
Genmab Receives FDA Breakthrough Therapy Designation for Rinatabart Sesutecan (Rina-S®) in Advanced Endometrial Cancer (EC)
Fonte
Genmab A/S
Emittente
Business Wire
1.00
0
02/06/2025
Biotecnologia
Sanità
Salute
Medicina - Varie
Oncologia
Eventi
Industria
Genmab Announces Investigational Rinatabart Sesutecan (Rina-S®) Demonstrates Encouraging Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer in Phase 1/2 RAINFOL™-01 Trial
Fonte
Genmab A/S
Emittente
Business Wire
1.00
0
22/05/2025
Eventi
Fiere
Industria
Biologia
Biotecnologia
Farmaceutica
Oncologia
Sanità
Salute
Igiene alimentare
Medicina - Varie
Genmab to Highlight New Data Evaluating Late-Stage Oncology Portfolio at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
Fonte
Genmab A/S
Emittente
Business Wire
1.00
0
14/05/2025
Eventi
Industria
Scienza
Biotecnologia
Farmaceutica
Oncologia
Sanità
Salute
Medicina - Varie
Genmab to Present New and Updated Results from its Robust Epcoritamab (EPKINLY®) Development Program at the 2025 European Hematology Association (EHA) Congress
Fonte
Genmab A/S
Emittente
Business Wire
1.00
0
02/05/2025
Industria
Scienza
Biotecnologia
Farmaceutica
Oncologia
Salute
Igiene alimentare
Medicina - Varie
Genmab to Submit Supplemental Biologics License Application (sBLA) to U.S. Food and Drug Administration for Epcoritamab Plus Rituximab and Lenalidomide (R2) in Patients with Relapsed/Refractory Follicular Lymphoma (FL)
Fonte
Genmab A/S
Emittente
Business Wire
1.00
0
31/03/2025
Industria
Scienza
Biotecnologia
Farmaceutica
Oncologia
Sanità
Salute
Medicina - Varie
TIVDAK® (tisotumab vedotin) Approved by European Commission for Previously Treated Recurrent or Metastatic Cervical Cancer
Fonte
Genmab A/S
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0